2022
Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.
Lacouture M, Patel A, LeBoeuf N, Marathe O, Leventhal J, Choi J, Lam E, Kaffenberger B, Voss M, Webb M, Tyler R, Ju J, Tang H, Luo J, Anadkat M, Vogelzang N. Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients. Journal Of Clinical Oncology 2022, 40: tps396-tps396. DOI: 10.1200/jco.2022.40.6_suppl.tps396.Peer-Reviewed Original ResearchHand-foot skin reactionPalmar-plantar erythrodysesthesiaProportion of patientsCTCAE v5.0IGA scoreSkin reactionsSevere hand-foot skin reactionMulti-targeted tyrosine kinase inhibitorWeek 3Nitric oxideInvestigator's Global Assessment (IGA) scaleLast patient visitVehicle-controlled trialPhase II studyVisual analog scaleVascular repair mechanismsTyrosine kinase inhibitorsGlobal Assessment ScaleInhibition of VEGFChi-square testIntra-rater reliabilityTopical stimulationTopical ureaPrimary endpointSecondary endpoints
2020
Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors
Coleman EL, Olamiju B, Leventhal JS. Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors. Oncology Reports 2020, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.Peer-Reviewed Original ResearchConceptsSevere cutaneous adverse reactionsTyrosine kinase inhibitorsLife-threatening severe cutaneous adverse reactionsAcute generalized exanthematous pustulosisEpidermal growth factor receptorStevens-Johnson syndromeCutaneous adverse reactionsToxic epidermal necrolysisVascular endothelial growth factorGrowth factor receptorAnaplastic lymphoma kinasePlatelet-derived growth factorAdverse reactionsFibroblast growth factor receptorFactor receptorApplication of TKIsGrowth factorHuman epidermal growth factor receptorKinase inhibitorsGeneralized exanthematous pustulosisPotential cutaneous toxicityEndothelial growth factorExanthematous pustulosisEpidermal necrolysisCutaneous toxicity